AnTolRx Company

At AnTolRx they are approaching the treatment of autoimmune diseases differently–through the development of novel nanoparticle-based therapies to promote antigen-specific immune tolerance. Standard therapies broadly suppress the immune system, inducing side effects that may include life threatening infections and tumors. Thus, there is an unmet clinical need for methods of targeted immune-regulation. Their proprietary drug development approach selectively targets pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases.
Technology: Others
Industry: Geroscience
Headquarters: Cambridge, Massachusetts, United States
Zip: 11-50
Founded Date: 2015-01-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Acquisitions Number: 3
Investors Number: 4000000
Total Funding: $1M to $10M
Estimated Revenue: $1M to $10M
Last Funding Date: Series A
Last Funding Type: kenison@antolrx.com

Visit Website
kenison@antolrx.com
https://www.crunchbase.com/organization/antolrx
Register and Claim Ownership